170 related articles for article (PubMed ID: 36346502)
1. Celebrating 80 years anniversary of radioiodine for use in thyroid cancer and perspectives for theranostics.
Hertz B; Watabe T; Baum RP
Ann Nucl Med; 2022 Dec; 36(12):1007-1009. PubMed ID: 36346502
[TBL] [Abstract][Full Text] [Related]
2. Celebrating eighty years of radionuclide therapy and the work of Saul Hertz.
Fahey FH; Grant FD
J Appl Clin Med Phys; 2021 Jan; 22(1):4-10. PubMed ID: 33533204
[TBL] [Abstract][Full Text] [Related]
3. Differentiated thyroid cancer theranostics: radioiodine and beyond.
Choudhury PS; Gupta M
Br J Radiol; 2018 Nov; 91(1091):20180136. PubMed ID: 30260232
[TBL] [Abstract][Full Text] [Related]
4. Theranostics in Thyroid Cancer.
Eilsberger F; Pfestroff A
PET Clin; 2021 Jul; 16(3):375-382. PubMed ID: 34053581
[TBL] [Abstract][Full Text] [Related]
5. Differentiated thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients.
Versari A; Sollini M; Frasoldati A; Fraternali A; Filice A; Froio A; Asti M; Fioroni F; Cremonini N; Putzer D; Erba PA
Thyroid; 2014 Apr; 24(4):715-26. PubMed ID: 24102584
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of positron emission tomography-assessed tumor heterogeneity in patients with thyroid cancer undergoing treatment with radiopeptide therapy.
Lapa C; Werner RA; Schmid JS; Papp L; Zsótér N; Biko J; Reiners C; Herrmann K; Buck AK; Bundschuh RA
Nucl Med Biol; 2015 Apr; 42(4):349-54. PubMed ID: 25595135
[TBL] [Abstract][Full Text] [Related]
7. Peptide Receptor Radionuclide Therapy (PRRT) of Medullary and Nonmedullary Thyroid Cancer Using Radiolabeled Somatostatin Analogues.
Salavati A; Puranik A; Kulkarni HR; Budiawan H; Baum RP
Semin Nucl Med; 2016 May; 46(3):215-24. PubMed ID: 27067502
[TBL] [Abstract][Full Text] [Related]
8. [Therapy concepts for thyroid carcinoma].
Eilsberger F; Kreissl MC; Luster M; Pfestroff A
Nuklearmedizin; 2022 Jun; 61(3):223-230. PubMed ID: 34644802
[TBL] [Abstract][Full Text] [Related]
9.
Parihar AS; Mittal BR; Kumar R; Shukla J; Bhattacharya A
Thyroid; 2020 Apr; 30(4):557-567. PubMed ID: 31870227
[No Abstract] [Full Text] [Related]
10. Peptide Receptor Radionuclide Therapy in Thyroid Cancer.
Gubbi S; Koch CA; Klubo-Gwiezdzinska J
Front Endocrinol (Lausanne); 2022; 13():896287. PubMed ID: 35712243
[TBL] [Abstract][Full Text] [Related]
11. Can peptide receptor radionuclide therapy (PRRT) be useful in radioiodine-refractory differentiated thyroid cancer?
Campennì A; Pignata SA; Baldari S
Endocrine; 2015 Nov; 50(2):516-8. PubMed ID: 25471282
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
13. Radiotheranostics - Precision Medicine in Nuclear Medicine and Molecular Imaging.
Duan H; Iagaru A; Aparici CM
Nanotheranostics; 2022; 6(1):103-117. PubMed ID: 34976584
[TBL] [Abstract][Full Text] [Related]
14. Radionuclide therapy beyond radioiodine.
Gabriel M
Wien Med Wochenschr; 2012 Oct; 162(19-20):430-9. PubMed ID: 22815123
[TBL] [Abstract][Full Text] [Related]
15. Molecular imaging of advanced thyroid cancer: iodinated radiotracers and beyond.
Santhanam P; Solnes LB; Rowe SP
Med Oncol; 2017 Oct; 34(12):189. PubMed ID: 29086115
[TBL] [Abstract][Full Text] [Related]
16. [Investigator-Initiated Clinical Trial of 211At-NaAt against Refractory Thyroid Cancer].
Watabe T
Gan To Kagaku Ryoho; 2022 Aug; 49(8):829-834. PubMed ID: 36046965
[TBL] [Abstract][Full Text] [Related]
17. The prostate-specific membrane antigen (PSMA)-targeted radiotracer
Santhanam P; Russell J; Rooper LM; Ladenson PW; Pomper MG; Rowe SP
Med Oncol; 2020 Oct; 37(11):98. PubMed ID: 33034761
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in nuclear medicine in endocrine oncology.
Luster M; Pfestroff A; Verburg FA
Curr Opin Oncol; 2017 Jan; 29(1):1-6. PubMed ID: 27906859
[TBL] [Abstract][Full Text] [Related]
19. From Bench to Bedside-The Bad Berka Experience With First-in-Human Studies.
Zhang J; Singh A; Kulkarni HR; Schuchardt C; Müller D; Wester HJ; Maina T; Rösch F; van der Meulen NP; Müller C; Mäcke H; Baum RP
Semin Nucl Med; 2019 Sep; 49(5):422-437. PubMed ID: 31470935
[TBL] [Abstract][Full Text] [Related]
20. Theranostic approaches in nuclear medicine: current status and future prospects.
Filippi L; Chiaravalloti A; Schillaci O; Cianni R; Bagni O
Expert Rev Med Devices; 2020 Apr; 17(4):331-343. PubMed ID: 32157920
[No Abstract] [Full Text] [Related]
[Next] [New Search]
